Hypoxia-inducible factor-1 (HIF-1) is a ubiquitously expressed oxygen-regulated transcription factor composed of a and b subunits. HIF-1 activates transcription of various genes including those involved in metastatic tumor growth. In the present study, HIF-1a expression in tumor-bearing mouse liver was examined after inoculation of tumor cells into portal vein. We found that tumor-bearing liver showed greatly increased HIF-1a expression. Plasmid DNA (pDNA) expressing short hairpin RNA targeting HIF-1a (pshHIF-1a) was effective in suppressing protein expression of HIF-1a in vitro. Intravenous injection of pshHIF-1a by hydrodynamics-based procedure reduced the HIF-1a protein expression in both normal and tumor cells and tumor cell number in the liver. Pre-injection of pshHIF-1a to mice, by which pDNA was delivered only to liver cells, not to tumor cells, was also effective in reducing the number of tumor cells inoculated 3 days after pDNA injection. These findings indicate that HIF-1a expression is increased in normal liver cells as well as tumor cells, and HIF-1a expression plays an important role in tumor progression. Use of the RNA interference (RNAi) of HIF-1 is an effective strategy for inhibiting tumor cell growth, and both tumor and normal cells can be the target for RNAi-based anticancer treatment.
Introduction
Metastasis, which is the transfer of cancer cells from one organ to other organs, is the most distinctive feature of malignant tumors and is the cause of approximately 90% of human cancer deaths. 1, 2 Tumor metastasis is an exceedingly complex process, which occurs through a series of sequential steps that include dissociation from the primary tumor, invasion of adjacent tissues, intravasation, transport through the circulatory system, arrest in small vessels, adhesion to endothelial cells, extravasation and growth in secondary organs. 3 It can be hypothesized that components of the secondary organ, such as endothelial cells, stromal cells, fibroblasts and parenchymal cells, are functionally organized to promote survival and proliferation of metastasizing cancer cells and generate a favorable microenvironment for cancer cells in metastatic sites. 4, 5 Hypoxia initiates a variety of cellular responses including the activation of hypoxia-inducible factor-1 (HIF-1). 6, 7 HIF-1 is a ubiquitously expressed heterodimeric transcription factor composed of a constitutively expressed b subunit and an oxygen-regulated a subunit. Under normal oxygen tension, the a subunit is continuously hydroxylated at conserved prolyl and asparaginyl residues and is targeted for degradation by the von Hippel-Lindau ubiquitin E3 ligase complex. 8 In hypoxia, inhibition of hydroxylation results in the stabilization of HIF-1a and its subsequent nuclear entry, which leads to transcriptional activation of target genes that stimulates angiogenesis, such as vascular endothelial growth factor (VEGF), that controls invasion of cancer cells, such as matrix metalloproteinases (MMPs), and promotes metabolic adaptation to hypoxia. 9 In general, tumor cells grow faster than the rate of angiogenesis so that tumor tissues are characterized by internal hypoxia. Therefore, activation of HIF-1 has been described in a variety of human cancers and their metastases. 10, 11 Moreover, although the role of HIF-1a in tumor cell growth has not been fully elucidated, our results and those from other groups have demonstrated that HIF-1a expression in tumor tissues is likely to help tumor cell survival and growth. 12, 13 RNA interference (RNAi) is an evolutionary conserved sequence-specific gene silencing mechanism, which can be triggered by small 21-to 25-nt doublestranded small interfering RNA (siRNA) or short hairpin RNA (shRNA) that is processed in the cell to form siRNA. 14, 15 Intravascular injection of a large-volume isotonic solution at a high speed is a very efficient method for delivering any solutes, including siRNA-and shRNA-expressing plasmid DNA (pDNA), to liver cells. This procedure, the so-called hydrodynamics-based procedure, has been applied to suppress expression of target genes in the liver. 16, 17 In addition to such application, we found that the hydrodynamic administration is also applicable to deliver siRNA-and shRNA-expressing pDNA to tumor cells in the liver. 18 Therefore, the hydrodynamics-based procedure can be an effective method to suppress the growth of tumor cells that are metastasized to the liver. Because the hydrodynamic administration can induce RNAi in both tumor cells in the liver and normal liver cells, suppressing the increased expression of a gene that aggravates the metastatic tumor growth in both tumor and liver cells can be an effective approach in treating hepatic metastasis. To this end, we selected HIF-1a as such a target gene in the present study. We applied the hydrodynamic injection method to administer shRNA-expressing pDNA targeting HIF-1a (pshHIF-1a) and found that the suppression of HIF-1a expression in the liver can suppress the growth of metastasizing tumor cells in that organ. Moreover, selective suppression of HIF-1a expression only in normal liver cells was found to be also effective in inhibiting metastatic tumor growth, indicating that HIF-1a expression in normal cells assisted the tumor progression.
Results
Reduction in protein expression of HIF-1a by shRNAexpressing pDNA
As previously reported by several groups, an enzymelinked immunosorbent assay (ELISA) analysis showed that addition of CoCl 2 increased the amount of HIF-1a proteins in Colon26 and B16-BL6 cells (Figure 1a) . Similar results were obtained when HIF-1a protein levels in Colon26 cells were evaluated by western blot analysis (Figure 1b) . Transfection of pshHIF-1a reduced the amount of HIF-1a protein, whereas transfection of control pDNA or pshGFP (green fluorescent protein) hardly affected the level of HIF-1a expression.
Using immunofluorescent staining with HIF-1a-specific antibody, localization of HIF-1a protein in the cells was visualized. While a weak signal of HIF-1a was observed in cytoplasm when cells were incubated without CoCl 2 , incubation of Colon26 cells with CoCl 2 resulted in nuclear accumulation of HIF-1a, which was detected as yellow signals as a result of overlap between the green fluorescence derived from HIF-1a and the red fluorescence derived from nuclear staining (Figure 1c) . Transfection of pshHIF-1a reduced the number of cells that show HIF-1a accumulation in their nucleus.
Inhibition of HIF-1 transcriptional activity by pshHIF-1a
To investigate whether pshHIF-1a is effective in suppressing the transcription activity of HIF-1, cells were transfected with a pDNA encoding luciferase gene under the control of hypoxia response element (HRE). In Colon26 cells, HRE-dependent luciferase expression from the reporter pDNA co-transfected with control pDNA or pshGFP was moderately increased by the addition of CoCl 2 . However, in B16-BL6 cells, HREdependent luciferase expression was increased by the addition of CoCl 2 compared with Colon26 cells (Figures  2a and b) . HRE-dependent luciferase expression in the presence of CoCl 2 was almost completely inhibited to about the expression level observed in the absence of CoCl 2 by transfection of pshHIF-1a. (Figures 3a-c) . In contrast, a strong HIF-1a signal was observed in the liver sections of tumor-bearing mice (Figure 3d ). In these pictures, increased HIF-1a expression was mainly observed in hepatic cells. Administration of control pDNA or pshGFP had little effect on HIF-1a expression induced by the inoculation of tumor cells (Figures 3e and f) . Moreover, hydrodynamic administration of pshHIF-1a reduced the signal intensity derived from HIF-1a protein compared with other tumor-bearing groups (Figure 3g ). By quantitatively analyzing relative areas of the HIF-1a expression (green signal) to the total area in the images, the percentage inhibition by pshHIF-1a was calculated to be about 20-30% of the other tumor-bearing groups. In addition, the administration of pshHIF-1a significantly (Po0.05) reduced the mRNA expression of HIF-1a in tumor-bearing liver, from 0.0059 ± 0.0011 copies relative to GAPDH mRNA (the control pDNA-treated group) to 0.0021 ± 0.0005.
Suppression of HIF-1a expression in liver by the pre-administration of pshHIF-1a
As it had been demonstrated that tumor inoculation via the portal vein induced HIF-1a accumulation in liver cells, we investigated whether the delivery of pshHIF-1a only to liver cells, not to tumor cells, affects tumor growth in the liver. To this end, tumor cells were inoculated 3 days after the hydrodynamic administration of pDNAs. Immunofluorescent staining for HIF-1a was performed at 2 days after tumor inoculation to investigate the HIF-1a expression level at that time (Figures 3h-l) . Similar to the results of the sample prepared at 7 days after tumor inoculation, a strong signal derived from HIF-1a protein was detected in the liver sections prepared at 2 days after tumor inoculation (Figure 3i ). To evaluate the effect of tumor inoculation via the portal vein on the MMP expression in the liver, the amount of MMP in liver homogenate was measured by gelatin zymography 8 days after tumor inoculation ( Figure 5a ). As we have reported previously, MMP-2 and -9 activities in the homogenate of tumor-inoculated liver was higher than that of the untreated group. A hydrodynamic delivery of control pDNA or pshGFP 5 days after tumor inoculation had little or no effect on both types of MMP activity. No significant increase in the MMP activity was detected in the liver homogenate of sham-operated mice or mice that received only pDNA. Intravenous injection of pshHIF-1a by the hydrodynamics-based procedure 5 days after tumor inoculation clearly reduced the MMP-9 gelatinolytic activity in the liver of tumor-bearing mice compared with the other tumor-inoculated group. Less, but detectable, reduction was also observed in the MMP-2 activity.
To assess the effect of HIF-1a expression in normal cells on MMP production, pshHIF-1a was administered 3 days before tumor inoculation. Gelatin zymography was performed at 3 days after tumor inoculation ( Figure  5b ). At this time point, the sham operation group showed slightly increased MMP-9 activity compared with naïve mice. Although the increase in MMP-9 expression level in the liver at this time was smaller than that detected at 8 days after tumor inoculation, the homogenate of tumor-bearing liver showed a higher MMP-9 activity than the other tumor-free groups. Pretreatment of pshHIF-1a reduced MMP-9 induction by tumor inoculation, while preinjection of control pDNA and Suppression of metastatic tumor growth in the liver by pshHIF-1a Figure 6a shows the tumor cell number in the liver, which was evaluated by measuring tumor-derived luciferase activities at 1 week after pDNA administration (Figure 6a ). Mice were inoculated with Colon26 cells into the portal vein, and each pDNA was injected into the tail vein with 5-day interval. Control pDNA or pshGFP hardly reduced the number of tumor cells, while pshHIF-1a significantly (Po0.05) reduced the number to about, on average, 1-2% of the other groups. Many large tumor nodules were found in the frozen liver sections of mice receiving control pDNA (Figure 6c ). In a quite contrast, much small and few tumor nodules were detected in the sections of mice receiving pshHIF-1a (Figure 6d ). These hematoxylin and eosin-stained sections strongly support the quantitative results of metastatic tumor growth estimated using the luciferase activity of Colon26/Luc cells ( Figure 6a) . Next, we investigated the effect of preadministration of pshHIF-1a on the growth of tumor cells in the liver by estimating the tumor cell number 12 days after tumor inoculation (Figure 6b) . As a result, pshHIF-1a preadministration 3 days before tumor inoculation significantly reduced the number of tumor cells in the liver 12 days after tumor inoculation compared with the groups that were untreated or given pDNA. On average, 
Discussion
HIF-1a expression and subsequent HIF-1 activation in cancer cells play important roles in cancer progression by controlling the gene expression related to cancer cell proliferation, apoptosis and metastasis. 9 In the present study, we demonstrated that HIF-1a expression in normal hepatic cells is also increased by tumor cells entering the liver via the portal vein and that such HIF-1a expression aggravates tumor growth. Our results indicate the possibility of a novel therapeutic strategy for inhibiting metastatic tumor growth by silencing the HIF-1a expression in both normal and tumor cells.
Suppression of nuclear accumulation of HIF-1a by pshHIF-1a ( Figure 1 ) was followed by inhibition of HIF-1-dependent transcription activities (Figure 2 ). In the experiment using pLuc-HRE, pshHIF-1a suppressed the transcription activity to almost the basal level in both Colon26 and B16-BL6 cells. Such an efficient inhibitory effect on luciferase expression might be because pLuc-HRE was co-transfected with pshHIF-1a, by which both pDNAs were delivered to the same cells. On the other hand, the suppressive effect of pshHIF-1a on VEGF production from B16-BL6 cells was much greater than that from Colon26 cells. Two factors may explain the difference in the efficiency of the inhibitory effect on VEGF production between B16-BL6 cells and Colon26 cells. One is the transfection efficiency of the pshHIF-1a. By using pDNA expressing enhanced green fluorescent protein (EGFP), we found that the transfection efficiency to B16-BL6 and Colon26 cells was about 80-90 and 70-80%, respectively, at 24 h after transfection (Y Takahashi et al., unpublished data). Therefore, the difference in transfection efficiency between B16-BL6 and Colon26 cells may be one reason for the difference in suppressive effect on VEGF production by pshHIF-1a. The other reason for the difference in suppression in the two cell lines could be the contribution of HIF-1-dependent VEGF production to the total VEGF production. Other hypoxiainducible transcriptional factors, such as HIF-2, are also known to be activated by CoCl 2 and increased HIF-2 expression might result in VEGF expression. 19 When tumor cells were inoculated via portal vein, HIF-1a protein expression was increased in tumorbearing liver (Figure 3) . Inoculation of DsRed-labeled Colon26 cells clearly demonstrated that liver cells close to the tumor cells expressed HIF-1a at a high level (Figure 4) . Oxygen concentration-dependent and -independent pathways might be considered as the mechanism for such an increase in HIF-1a expression. When tumor cells are inoculated via the portal vein, tumor cells are first arrested in small vessels, followed by extravasation, invasion of tissues and proliferation of tumor cells. 3 Therefore, blood flows would be, at least transiently, hindered by tumor cells, which could result in a reduction in the oxygen supply. In addition to hypoxia, other processes such as growth factor stimulation and cytokine stimulation are reported to increase HIF-1a expression and activate HIF-1-dependent transcription. 9, 20 When tumor cells metastasize to the liver, expression of these secretary proteins might be induced and result in increased HIF-1a expression.
To distinguish the role of HIF-1a expressed in tumor cells from that in normal liver cells, pshHIF-1a was administered 3 days before tumor inoculation. As pDNA injected into the systemic circulation is very quickly degraded by nucleases and cleared by Kupffer and sinusoidal endothelial cells, 21 pDNA injected would have hardly any effects on the expression level of HIF-1a in Colon26/Luc cells. On the other hand, when pshHIF1a was administered after tumor inoculation, pshHIF-1a might be delivered to both tumor and liver cells. 18 Therefore, pshHIF-1a administered before tumor inoculation might have been delivered only to normal cells in the liver, while pshHIF-1a administered after tumor inoculation might have been delivered to both tumor and normal cells in the liver.
In a previous study, we reported that Colon26 cell inoculation via the portal vein increased MMP-9 expression in the liver. 22 Elezkurtaj et al. 23 demonstrated that intrasplenic inoculation of CT-26 colon carcinoma cells, which form experimental liver metastases, increased MMP-2 and -9 expressions in liver tissue. In agreement with these results, we have found that MMP-9 is generated mainly from host cells, not the inoculated tumor cells (Y Takahashi et al., unpublished data). There are some published papers reporting that MMP-9 expression is directly or indirectly regulated by HIF-1.
24-26 Therefore, we hypothesized that increased HIF-1 transcription activity in normal cells in the liver contributes to MMP-9 production induced by tumor cell inoculation. Intravenous administration of pshHIF-1a was effective in reducing the expression of MMP-9 after tumor inoculation, which indicates that HIF-1 expression in tumor cells and normal cells in the liver might play an important role in MMP-9 production. Moreover, administration of pshHIF-1a before tumor inoculation was found to be also effective in reducing the amount of MMP-9 in the liver. This result reinforces the hypothesis that normal cells in the liver, not tumor cells, are the major producer of MMP-9 and that MMP-9 expression is regulated by HIF-1. Although its role in metastatic tumor cell growth is still unclear, increased MMP expression is frequently accompanied by tumor metastasis and suppression of MMP expression could be used as a growth inhibitory treatment to prevent tumor metastasis. 23, 27, 28 When pshHIF-1a was administered to tumor-bearing mice by the hydrodynamics-based procedure, a significant reduction in the number of tumor cells was observed (Figure 6a ). This result indicates that HIF-1a expression in either tumor cells or hepatic normal cells or in both types of cells plays an important role in tumor progression. A histological study of the liver sections confirmed that the administration of pshHIF-1a significantly reduced the metastatic tumor growth in the liver (Figures 6c and d) . Preadministration of pshHIF-1a reduced the tumor cell number in the liver at 12 days after tumor inoculation compared with the other groups (Figure 6b ). This result implies that HIF-1a expression in the normal cells in the liver might play an important role in tumor cell growth in the liver, although the reduction in the tumor cell number was modest compared with the case where the pshHIF-1a was administered after tumor inoculation. As demonstrated in our previous study, hydrodynamic delivery of pDNA can deliver pDNA to tumor cells in the liver. Moreover, we and other groups have reported that intratumoral expression of HIF-1a helps cancer cell survival and proliferation as well as angiogenesis and cancer metastasis. Therefore, hydrodynamic administration of pshHIF-1a could suppress HIF-1a expression in tumor cells, which might also act as an inhibitory treatment to prevent tumor progression. When HIF-1a expression is increased in normal cells, it might result in upregulation of genes that can assist tumor cell growth and progression. In the present study, we focused on MMP-9 as an HIF-1-dependent tumor supportive protein produced from normal cells. Normal cells, including hepatocytes, have significantly fewer genetic mutations than cancer cells. Therefore, inhibiting the increase in HIF-1a expression in hepatocytes would have less chance of inducing resistance to treatment.
In conclusion, this study suggests that HIF-1a expression is increased in normal liver cells as well as cancerous cells, and HIF-1a expression plays an important role in tumor progression. RNAi of HIF-1 is an effective strategy for inhibiting tumor cell growth, and both tumor and normal cells can be targets for RNAibased anticancer treatment.
Materials and methods

Plasmid DNA
Short hairpin-expressing pDNAs targeting GFP or HIF-1a were constructed from piGENE hU6 vector (iGENE Therapeutics, Tsukuba, Japan) as described previously. 18 Target sites in GFP and murine HIF-1a genes are as follows: GFP, 5 0 -GGCTACGTCCAGGAGCGCA-3 0 and HIF-1a, 5 0 -GACACAGCCTCGATATGAA-3 0 . These pDNAs transcribe a stem-loop-type RNA with a loop sequence of ACGUGUGCUGUCCGU. In a previous study, we confirmed that transfection of pshHIF-1a suppresses the mRNA expression of HIF-1a in cultured cells. 13 piGENE hU6 vector, which transcribes a nonrelated sequence of RNA with partial duplex formation, was used as a control pDNA throughout the present study.
pDsRed2-N1 encoding red fluorescent protein Dsred2 was purchased from BD Biosciences Clontech (Palo Alto, CA, USA). pGL4.74[hRluc/TK] (phRL-TK) encoding sea pansy luciferase under the control of herpes simplex virus TK promoter was purchased from Promega (Madison, WI, USA). A HRE reporter plasmid encoding firefly luciferase (pLuc-HRE) was generated by subcloning nine copies of the HRE (5 0 -TACGTGCTGC-3 0 ) from mouse erythropoietin enhancer into BglII/ HindIII site of pLuc-MCS plasmid (Stratagene, La Jolla, CA, USA).
Each pDNA was amplified in the DH5a strain of Escherichia coli and purified by using a Qiagen Endofree Plasmid Giga Kit (Qiagen GmbH, Hilden, Germany).
Cell culture
A murine colon carcinoma cell line Colon26, obtained from the Cancer Chemotherapy Center of the Japanese Foundation for Cancer Research (Tokyo, Japan), and Colon26 cells that stably express firefly luciferase (Colon26/Luc) 29 were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin/L-glutamine at 37 1C and 5% CO 2 . A murine melanoma cell line B16-BL6 cells 30 , obtained from the Cancer Chemotherapy Center of the Japanese Foundation for Cancer Research, were cultured in Dulbecco's modified Eagle's minimum essential medium (DMEM; Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FBS and penicillin/streptomycin/L-glutamine at 37 1C and 5% CO 2 . To mimic hypoxic conditions and induce HIF-1a protein expression, cells were incubated with the culture medium supplemented with 100 mM CoCl 2 . 31 
In vitro transfection
Tumor cells were plated on culture plates. After an overnight incubation, transfection of pDNA was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. In brief, 1 mg pDNA was mixed with 3 mg Lipofectamine 2000 at a final concentration of 2 mg pDNA ml À1 dissolved in OPTI-MEM I (Invitrogen). The resulting complex was added to the cells and the cells were incubated with the complex for 4 h. Cells were washed with PBS and further incubated with the culture medium supplemented with or without 100 mM CoCl 2 for the indicated periods.
Detection of HIF-1a protein expression by western blotting and ELISA
At 24 h after transfection, total proteins were collected from Colon26 and B16-BL6 cells. For total protein extraction, cells were lysed in a lysis buffer containing 50 mM Tris (pH 7.4), 1% NP40, 0.25% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM NaF and 0.2% Sigma protease inhibitor cocktail (Sigma Aldrich, St Louis, MO, USA). The lysate was centrifuged at 13 000 g for 20 min at 4 1C and the supernatant was collected and used as a protein sample. Protein concentrations were determined using a Proteostain Protein Quantification Kit (Dojindo Molecular Technologies Inc., Tokyo, Japan).
For western blotting, 50 mg protein was diluted with a loading buffer, denatured at 95 1C for 3 min, and resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (6.5% polyacrylamide) and transferred to a polyvinylidene fluoride membrane (Immobilon-P; Millipore Corp., Bedford, MA, USA) by semidry blotting with Transblot SD (Bio-Rad, Hercules, CA, USA). To avoid nonspecific binding, the membrane was incubated in 5% bovine serum albumin. Then HIF-1a protein was detected by a primary monoclonal mouse antibody against HIF-1a (1:500; Novus Biologicals, Littleton, CO, USA) and a secondary peroxidase-conjugated rabbit antimouse IgG antibody (1:2000; Amersham Biosciences Inc., Piscataway, NJ, USA). Protein bands were visualized by chemiluminescence on the ECL Plus protein detection system (Amersham Biosciences).
Concentrations of HIF-1a in the samples from tumor cells treated with or without CoCl 2 were measured by an ELISA kit (DuoSet IC; R&D Systems, Minneapolis, MN, USA) according to manufacturer's protocol. ) and a control pDNA, pshHIF-1a or pshGFP (1 mg ml À1 ) using Lipofectamine 2000 as described above. At 4 h after transfection, cells were washed with PBS and further incubated with the culture medium with or without 100 mM CoCl 2 for an additional 20 h. Then cells were lysed using Promega passive lysis buffer (Promega). Samples were mixed with dual-luciferase reporter system (Promega) and the chemiluminescence produced was measured in a luminometer (Lumat LB9507; EG and G Berthold, Bad Wildbad, Germany). The results were calculated as the activity of firefly luciferase relative to that of sea pansy luciferase to correct for differences in transfection efficiency. The ratios of CoCl 2 -treated cells were normalized to give x-fold values relative to those of the corresponding untreated group.
Animals
Four-week-old male BALB/c mice (approximately 20 g body weight), purchased from Shizuoka Agricultural Cooperative Association (Shizuoka, Japan), were used in all experiments. All animal experiments were conducted in accordance with the principles and procedures outlined in the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocols for animal experiments were approved by the Animal Experimentation Committee of the Graduate School of Pharmaceutical Sciences of Kyoto University.
Hepatic metastasis of tumor cells
Colon26/Luc cells in an exponential growth phase were harvested by trypsinization and suspended in Hank's balanced salt solution (HBSS; Nissui Pharmaceutical). Under ether anesthesia, a midline abdominal incision was made to expose the portal vein, and 1 Â 10 5 Colon26/Luc cells were injected into the portal vein. Then the opening was sutured and mice were allowed to recover. At 5 days after tumor inoculation, mice received an intravenous injection of pDNA at a dose of 2.5 mg kg À1 body weight. The intravenous injection was performed by the hydrodynamics-based procedure where pDNA dissolved in saline in a volume of 8% of the body weight was injected into the tail vein within less than 5 s using a 26-gauge needle. 32 To evaluate the effect of HIF-1a expression in normal liver cells on the growth of tumor cells in the liver, mice received a hydrodynamic delivery of pDNA, followed by inoculation of tumor cells into the portal vein after an interval of 3 days.
To visualize the location of Colon26 cells in the liver, Colon26 cells labeled with a red fluorescent protein, DsRed, were used instead of Colon26/Luc cells. DsRed2-labeled Colon26 cells were prepared by transfecting cells with pDsRed2-N1, and inoculated into mice 24 h after transfection.
Immunofluorescent staining of HIF-1a
To visualize HIF-1a expression in cultured cells, immunofluorescent staining of HIF-1a was carried out. At 24 h after transfection, cells were fixed with 4% paraformaldehyde in PBS. The cell membrane was permeabilized by PBS containing 0.1% Triton X-100. After blocking with 10% FBS in PBS, cells were incubated with a monoclonal mouse antibody against HIF-1a (1:500; Novus Biologicals). After washing, Alexa Fluor 488 goat anti-mouse secondary antibody (1:600; Molecular Probes, Invitrogen) was added. Nuclear staining was performed using propidium iodide staining solution (50 mg ml À1 propidium iodide and 1 mg ml À1 RNase A in PBS). Slides were prepared using a SlowFade Antifade Kit (Molecular Probes). Samples were examined using a confocal laser microscope (MRC-1024; Bio-Rad).
For the detection of HIF-1a expression in the liver, mice under ether anesthesia were euthanized by cutting the vena cava, and the liver was gently infused with 2 ml saline through the portal vein to remove the remaining blood in the organ. The liver was then placed in TissueTek OCT embedding compound (Sakura Finetechnical Co Ltd, Tokyo, Japan), frozen in liquid nitrogen, and stored in 2-methyl butanol at À80 1C until use. Frozen liver sections (8 mm thick) were obtained with a cryostat (Jung CM 3000; Leica Microsystems AG, Wetzlar, Germany) using a routine procedure. Sections were stained with HIF-1a-specific antibody by the same procedure as cultured cells except for the blocking process. Liver sections were blocked using the Vector M.O.M Immunodetection Kit (Vector Laboratories, Burlingame, CA, USA). Sections were examined using a confocal laser microscope. Relative areas of the HIF-1a expression (green signal) to the total area in the images were quantitatively analyzed by using a BZ-Analyzer software (KEYENCE, Osaka, Japan).
Gelatin zymography
At 3 or 8 days after tumor inoculation, mice under ether anesthesia were euthanized by cutting the vena cava. The liver was gently infused with 2 ml saline through the portal vein to remove the remaining blood. The liver was excised and homogenized in 5 ml g À1 lysis buffer (0.1 M Tris (pH 7.8), 0.05% Triton-X-100). The homogenate was centrifuged at 13 000 g for 20 min at 4 1C, then the supernatant was collected. For the measurement of gelatinase activity, 500 mg protein was electrophoresed under non-reducing conditions on 10% SDS-polyacrylamide gel containing 0.1% gelatin. Gels were washed twice for 30 min in 2.5% Triton X-100 and once for 30 min in 10 mM Tris-HCl (pH 8.0) and incubated overnight in 50 mM Tris-HCl (pH 8.0) containing 10 mM CaCl 2 and 10 nM ZnCl 2 . The gels were then stained with 0.2% Coomasie brilliant blue and destained in 5% methanol and 7% acetic acid.
VEGF ELISA assay
To determine VEGF production in culture supernatants in vitro, tumor cells seeded on culture plates were transfected as described above and supernatants were collected for ELISA 48 h after the transfection. VEGF protein levels in the supernatant were measured using mouse VEGF-specific ELISA (Quantikine; R&D systems).
Inhibitory effect of pshHIF-1a on tumor growth in the liver At 12 days after tumor inoculation, mice were euthanized by cervical dislocation and the liver was excised and homogenized in a lysis buffer (0.1 M Tris (pH 7.8), 0.05% Triton X-100, 2 mM EDTA), and centrifuged at 13 000 g for 20 min at 4 1C. The supernatant was mixed with a luciferase assay buffer (Picagene; Toyo Ink, Tokyo, Japan), and the light produced was measured with a luminometer (Lumat LB 9507). The luciferase activity of the liver was converted to the number of Colon26/Luc cells using a regression line as previously reported. 29 Different sets of mice were used for the histological evaluation of tumor-bearing livers. At 12 days after tumor inoculation, frozen liver sections were made as described above and stained with hematoxylin and eosin, followed by an examination using a microscope (Biozero BZ-8000; KEYENCE).
Statistical analysis
Experiments were performed at least in duplicate, and a typical set of data was indicated. Differences were statistically evaluated by Student's t-test. A P-value of less than 0.05 was considered to be statistically significant.
